Back Back
RCB1960 : HuCCT1  update : 2018/08/01
CommentHuman bile duct carcinoma. This cell line produces carbohydrate antigen 19/9 in serum-free medium. TKG0389 (Deposited from Tohoku Univ.).
Comment from the depositor
Restriction (Category)a
Terms and conditionsBasically, there is no restriction regarding academic use.
Order Form Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, Category I and II, depending on the sort of user institutions and the purposes of use.Please use an appropriate MTA(to see).In case of Restriction "a" or "f", please contact RIKEN BRC( regarding any kind of for-profit use.
Basic information Depositor Obinata, Masuo
Originator Miyagiwa, M. (Okayama Univ.)
Year of deposit 2004
Original cell TKG0389
Animal human < Mammals
Genus Homo
Species sapiens
Age at sampling 56 years
Tissue bile duct, ascites meta
Case history bile duct carcinoma.
Metastastatic ability Yes
Metastatsd tissue asites
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG0389)
Lifespan infinite
Morphology epithelial-like
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
STR (human) OK
Virus (HBV) (-)
Virus (HCV) (-)
Isozyme LD, NP
deposit info
lot info
Reference information Reference 1
User's Publication 20

To topTop
Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H  A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium  In Vitro Cell Dev Biol Anim  1989  25:503-510 

To topTop
User's Publication
Agarinis C, Orsini V, Megel P, Abraham Y, Yang H, Mickanin C, Myer V, Bouwmeester T, Tchorz JS, Parker CN.  Activation of Yap-Directed Transcription by Knockdown of Conserved Cellular Functions.  J Biomol Screen  2015  21:269-76  PubMed ID: 26637552
Xu YF, Ge FJ, Han B, Yang XQ, Su H, Zhao AC, Zhao MH, Yang YB, Yang J.  High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma.  World J. Gastroenterol.  2015  21:3256-65  PubMed ID: 25805932
Nakamura K, Nakabayashi K, Htet Aung K, Aizawa K, Hori N, Yamauchi J, Hata K, Tanoue A.  DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status.  PLoS ONE  2015  10:e0120545  PubMed ID: 25799509
Iwahashi S, Ishibashi H, Utsunomiya T, Morine Y, Ochir TL, Hanaoka J, Mori H, Ikemoto T, Imura S, Shimada M.  Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.  J. Med. Invest.  2011  58:106-9  PubMed ID: 21372494
Sato A, Kudo C, Yamakoshi H, Uehara Y, Ohori H, Ishioka C, Iwabuchi Y, Shibata H.  Curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-κB signaling and induces apoptosis.  Cancer Sci.  2011  102:1045-51  PubMed ID: 21272158
Samatiwat P, Takeda K, Satarug S, Ohba K, Kukongviriyapan V, Shibahara S.  Induction of MITF expression in human cholangiocarcinoma cells and hepatocellular carcinoma cells by cyclopamine, an inhibitor of the Hedgehog signaling.  Biochem. Biophys. Res. Commun.  2016  470:144-9  PubMed ID: 26773496
Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.  Src as a Therapeutic Target in Biliary Tract Cancer.  Mol. Cancer Ther.  2016  15:1515-24  PubMed ID: 27196758
Edeline J, Coulouarn C, Crouzet L, Pracht M, Lepareur N, Clément B, Garin E.  Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.  J Vasc Interv Radiol  2015  26:1874-78.e2  PubMed ID: 26596183
Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS.  High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.  Mol. Carcinog.  2017  56:2146-2157  PubMed ID: 28467612
Račkauskas R, Zhou D, Ūselis S, Strupas K, Herr I, Schemmer P.  Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti-apoptotic proteins.  Oncol. Rep.  2017  37:3660-3666  PubMed ID: 28498473
Li P, Zhang L, Yang M, Qi M, Jin X, Han B.  Cul4B is a novel prognostic marker in cholangiocarcinoma.  Oncol Lett  2017  14:1265-1274  PubMed ID: 28808481
Nooron N, Ohba K, Takeda K, Shibahara S, Chiabchalard A.  Dysregulated Expression of MITF in Subsets of Hepatocellular Carcinoma and Cholangiocarcinoma.  Tohoku J. Exp. Med.  2017  242:291-302  PubMed ID: 28794318
Kawashita Y, Morine Y, Saito Y, Takasu C, Ikemoto T, Iwahashi S, Teraoku H, Yoshikawa M, Imura S, Yagi T, Shimada M.  Role of heat shock factor 1 expression in the microenvironment of intrahepatic cholangiocarcinomas.  J. Gastroenterol. Hepatol.  2018    PubMed ID: 29278438
Merdrignac A, Angenard G, Allain C, Petitjean K, Bergeat D, Bellaud P, Fautrel A, Turlin B, Clément B, Dooley S, Sulpice L, Boudjema K, Coulouarn C.  A novel transforming growth factor beta-induced long noncoding RNA promotes an inflammatory microenvironment in human intrahepatic cholangiocarcinoma.  Hepatol Commun  2018  2:254-269  PubMed ID: 29507901
Sakamoto Y, Yamagishi S, Tanizawa Y, Tajimi M, Okusaka T, Ojima H.  PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay.  Jpn. J. Clin. Oncol.  2018  48:396-399  PubMed ID: 29474549
Komatsu N, Kajiya M, Motoike S, Takewaki M, Horikoshi S, Iwata T, Ouhara K, Takeda K, Matsuda S, Fujita T, Kurihara H.  Type I collagen deposition via osteoinduction ameliorates YAP/TAZ activity in 3D floating culture clumps of mesenchymal stem cell/extracellular matrix complexes.  Stem Cell Res Ther  2018    PubMed ID: 30526677
Kim J, Kim H, Lee JC, Kim JW, Paik WH, Lee SH, Hwang JH, Ryu JK, Kim YT.  Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.  PLoS ONE  2018    PubMed ID: 30557411
Brun S, Bassissi F, Serdjebi C, Novello M, Tracz J, Autelitano F, Guillemot M, Fabre P, Courcambeck J, Ansaldi C, Raymond E, Halfon P.  GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma.  Invest New Drugs  2019    PubMed ID: 30778887
Farley AM, Braxton DR, Li J, Trounson K, Sakar-Dey S, Nayer B, Ikeda T, Lau KX, Hardikar W, Hasegawa K, Pera MF.  Antibodies to a CA 19-9 Related Antigen Complex Identify SOX9 Expressing Progenitor Cells In Human Foetal Pancreas and Pancreatic Adenocarcinoma.  Sci Rep  2019    PubMed ID: 30814526
Wei K, Li M, Zöller M, Wang M, Mehrabi A, Hoffmann K.  Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.  Cell Death Dis  2019    PubMed ID: 30850583

Back Back Return Top Page